Financial Performance - For the fiscal year 2023, the company's total revenue was approximately HKD 1,001.7 million, a decrease of about 10.7% compared to HKD 1,121.8 million in fiscal year 2022[22]. - The revenue from primary care services decreased by approximately HKD 135.1 million or 14.2% to about HKD 819.1 million, primarily due to reduced demand for COVID-19 related services[22]. - The revenue from specialist medical services increased by approximately HKD 11.0 million or 10.5% to about HKD 115.4 million, driven by an increase in patient visits and average spending per visit[23]. - The gross profit for fiscal year 2023 was approximately HKD 593.2 million, a decrease of about HKD 66.4 million or 10.1% from HKD 659.7 million in fiscal year 2022[27]. - The gross profit margin slightly increased from approximately 58.8% in fiscal year 2022 to about 59.2% in fiscal year 2023[27]. - The company's net profit for fiscal year 2023 was approximately HKD 180.8 million, a decrease of about HKD 194.5 million from HKD 375.3 million in fiscal year 2022[39]. - The effective tax rate increased from approximately 15.7% in fiscal year 2022 to about 24.3% in fiscal year 2023[38]. - The company's profit attributable to owners for the fiscal year 2023 was approximately HKD 180.8 million, a decrease of 51.8% compared to HKD 375.3 million in fiscal year 2022[40]. - Overall revenue for fiscal year 2023 decreased by approximately 10.7% compared to fiscal year 2022, primarily due to a significant drop in demand for pandemic-related services in the second half of the fiscal year[42]. Operational Developments - The company launched a large flagship health center, H2, which integrates various medical and health technology services, enhancing customer service quality[14]. - A new membership program was introduced to increase customer engagement and satisfaction, offering exclusive promotions and personalized recommendations[14]. - Strategic partnerships were established with United Medical Group and Biomedical Technology Holdings, aimed at enhancing operational efficiency and innovation in healthcare solutions[15]. - The company is focused on digital transformation, upgrading IT infrastructure and developing a new integrated clinic operation platform to improve customer experience[16]. - Investment in a smart health ecosystem is underway, leveraging advanced technology and data analytics to meet community health needs[18]. - The company aims to enhance its position as a leading healthcare service provider through continuous adaptation and strategic initiatives[12]. - The company plans to expand its ophthalmology services and continue digitalization and automation efforts to enhance operational efficiency[22]. - The company remains committed to providing high-quality healthcare services despite anticipated revenue challenges in the primary care segment for fiscal year 2024[22]. Market Trends and Challenges - The overall economic recovery post-COVID-19 has positively impacted the company's operations, although challenges and uncertainties remain in the global economic outlook[11]. - The group remains optimistic about the post-pandemic healthcare market potential in Hong Kong, driven by increased health awareness and rising visitor numbers[65]. - The group plans to enhance operational efficiency and expand service offerings in response to market trends and demands[65]. - For the fiscal year 2024, the group anticipates challenges in general healthcare service revenue due to the cessation of pandemic-related services but remains committed to providing high-quality healthcare and exploring new business opportunities[72]. Employee and Management Structure - The group employs a professional team of 558 members, including general practitioners, specialists, and other healthcare professionals, to provide comprehensive services[64]. - The total number of full-time employees decreased to 428 as of June 30, 2023, from 542 in 2022, while part-time employees decreased to 426 from 1,157[88]. - The company continues to recruit based on market conditions and business needs, with a focus on professional healthcare staff[88]. - The company has established a cautious evaluation standard for hiring healthcare professionals, considering experience, skills, and competencies[88]. - The management team is focused on developing comprehensive business plans to drive growth and operational efficiency[109]. Corporate Governance - The company has been expanding its board with independent non-executive directors to enhance governance and oversight[101][105]. - The company has adopted the corporate governance code as its governance framework, ensuring compliance with all applicable code provisions for the fiscal year 2023[116]. - The board of directors is responsible for approving the company's strategic planning and major financial matters, including significant transactions and investments[121]. - The company emphasizes the importance of independent external auditors in maintaining financial integrity and transparency[155]. - The audit committee consists of three independent non-executive directors, ensuring oversight of financial reporting and compliance[152]. Shareholder Relations - The company encourages ongoing communication with shareholders through various channels, including interim and annual reports[179]. - The company welcomes shareholder inquiries and feedback through its website, promoting transparency and open communication[180]. - The board has proposed a final dividend of HKD 0.16 per share for the fiscal year 2023, down from HKD 0.30 in fiscal year 2022[190]. - The company has maintained its core business of providing comprehensive and quality healthcare services without significant changes in the nature of its operations during fiscal year 2023[188]. - The company continues to enhance investor relations and communication with shareholders and potential investors[183].
盈健医疗(01419) - 2023 - 年度财报